NZOZ Evita Sp. z o.o.

At NZOZ Evita Sp. z o.o. in Bialystok, clinical trials in respiratory medicine focus on improving care for people with severe eosinophilic asthma and chronic obstructive pulmonary disease. The studies are designed to assess new treatment options and better understand how they can reduce symptoms and asthma attacks while supporting lung function.

• Testing a new therapy for paediatric and adolescent asthma with frequent exacerbations
• Evaluating treatment effectiveness in COPD to improve major cardiopulmonary outcomes
• Studying the impact of eosinophilic inflammation on long-term breathing control

These trials reflect a strong interest in advancing practical, patient-focused approaches to chronic lung disease and uncontrolled airway inflammation.

Research at this site also includes ear, nose, and throat conditions, especially chronic rhinosinusitis with nasal polyps. The trials aim to improve symptom relief, reduce nasal blockage, and evaluate whether new treatments can ease the burden of persistent sinus disease.

• Assessing a new option for reducing nasal congestion and polyp severity
• Exploring patients’ experiences of CRSwNP and treatment satisfaction
• Understanding how therapy changes the daily impact of sinus symptoms

This area combines clinical evaluation with patient-reported insights, helping researchers better capture both measurable improvement and the lived experience of CRSwNP.

The site is also involved in studies of type 2 diabetes, a major metabolic disease affecting blood sugar control. These trials are focused on testing whether new treatment approaches can lower HbA1c more effectively in people whose diabetes remains inadequately controlled.

• Comparing different treatment options for better blood glucose control
• Evaluating the effectiveness of a new medicine for type 2 diabetes
• Studying responses in participants already using standard diabetes therapy

Overall, the diabetes research at NZOZ Evita Sp. z o.o. is centered on improving everyday metabolic management and identifying therapies that may offer stronger long-term control.